Moderna Inc. (MRNA)
MRNA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/0001682852-26-000033-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MRNA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001682852 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.9B |
| Net income | -$2.8B |
| Operating income | -$3.1B |
| Net margin | -145.2% |
| Operating margin | -158.1% |
| Revenue growth | -39.9% |
| Cash | $2.6B |
| Total assets | $12.3B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 44.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $1.2B cash; operating cash flow -$446.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 404,620,975 (2026-10-30); 390,679,512 a year earlier; 381,283,996 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $64.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.3B | $162.0M | -$1.6B | $1.2B | No debt tags | $2.5B | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $145.0M | -$782.0M | -$526.0M | $1.7B | $591.0M | $2.2B | 10-Q 2026-07-31 |
| Q1 2026 2026-03-31 | $389.0M | -$1.3B | -$630.0M | $1.9B | $590.0M | $2.2B | 10-Q 2026-05-01 |
| Q4 2025 2025-12-31 | $678.0M | -$826.0M | $930.0M | $2.6B | $590.0M | $1.9B | 10-K 2026-02-20 |
| Q3 2025 2025-09-30 | $1.0B | -$200.0M | -$847.0M | $1.1B | No debt tags | $2.2B | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $142.0M | -$825.0M | -$919.0M | $1.3B | No debt tags | $3.1B | 10-Q 2026-07-31 |
| Q1 2025 2025-03-31 | $108.0M | -$971.0M | -$1.0B | $1.6B | No debt tags | $3.2B | 10-Q 2026-05-01 |
| Q4 2024 2024-12-31 | $966.0M | -$1.1B | $825.0M | $1.9B | $0 | $3.2B | 10-K 2026-02-20 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2023-05-05 |
| Latest annual report | 10-K | 2026-02-20 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-03-16 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.1% |
| 1 month | +3.3% |
| 3 months | +250.9% |
| Year to date | +657.4% |
| 1 year | +794.9% |
| From 52-week high | -17.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ARGX | argenx SE | $950.95 | -0.95% | $59.0B |
| BIIB | Biogen Inc. | $251.65 | -0.69% | $37.2B |
| GILD | Gilead Sciences Inc. | $167.58 | -0.30% | $207.9B |
| RVMD | Revolution Medicines Inc. | $166.87 | -3.15% | $36.1B |
| AMGN | Amgen Inc. | $462.32 | -0.72% | $250.1B |
| BNTX | BioNTech SE American Depositary Share | $85.26 | -0.40% | $21.4B |
| NBIX | Neurocrine Biosciences Inc. | $165.31 | -1.25% | $16.7B |
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier